Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group | Zendy

Todd M. Cooper | Zendy; Michael J. Absalon | Zendy; Todd A. Alonzo | Zendy; Robert B. Gerbing | Zendy; Kasey J. Leger | Zendy; Betsy Hirsch | Zendy; Jessica A. Pollard | Zendy; Bassem I. Razzouk | Zendy; Richard Aplenc | Zendy; E. Anders Kolb | Zendy

Open Access

Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

Author(s) -

Todd M. Cooper,

Michael J. Absalon,

Todd A. Alonzo,

Robert B. Gerbing,

Kasey J. Leger,

Betsy Hirsch,

Jessica A. Pollard,

Bassem I. Razzouk,

Richard Aplenc,

E. Anders Kolb

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.03306

Subject(s) - medicine , cytarabine , fludarabine , neutropenia , absolute neutrophil count , granulocyte colony stimulating factor , febrile neutropenia , gastroenterology , regimen , phases of clinical research , flag (linear algebra) , myeloid leukemia , surgery , chemotherapy , cyclophosphamide , mathematics , pure mathematics , algebra over a field

Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of daunorubicin and cytarabine. AAML1421 sought to determine the recommended phase II dose (RP2D) of CPX-351 and the response rate after up to 2 cycles of therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research